DSCAM and breast cancer: As indicated by TCGA dataset, higher DSCAM-AS1 expression was associated with better prognosis in BC patients; however, overexpression of DSCAM-AS1 was conversely associated with poor clinical outcomes in both ER-positive and -negative BC.